Contact Information:InvestorsWill O'ConnorStern Investor Relations, Inc.email@example.comDoug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
HOUSTON, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2016 American Society of Hematology (ASH) Annual Meeting, taking place from December 3-6, 2016 in San Diego, CA. Dr. Ana Tari Ashizawa, Director of Research at Bio-Path, will present preclinical and clinical data of BP1001 (Liposomal Grb2 antisense) for the treatment of chronic myeloid leukemia (CML). Details for the poster presentation are as follows: Date: Monday, December 5, 2016 Presentation Time: 6:00 pm - 8:00 pm Pacific Time Location: San Diego Convention Center, Hall GH Session: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy Abstract: 4293 Title: "BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia" (Link to abstract) About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. For more information, please visit the Company's website at http://www.biopathholdings.com.